More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Of patients who started a new pill prescription, 21.1% had previously taken the injectable version of Wegovy and 15.8% switched from Eli Lilly's Zepbound, another injectable GLP-1 medicine, according to Truveta data. Truveta reviewed health records from 8,762 patients with evidence of a prescription for the new Wegovy pill, which was approved by the U.S. Food and Drug Administration on December 22.
Advertisement
ALSO READ
-
Novo Nordisk's Strategic Win Amid Patent Battle and Market Pressures
-
Novo Nordisk's Stock Surge Amid Hims & Hers' Weight-Loss Pill Halt
-
Novo Nordisk's Legal Battle Over Wegovy Counterfeit
-
Novo Nordisk's Strategic Gamble: Navigating the Obesity Drug Price Wars
-
New play in Denmark charts Novo Nordisk's weight loss boom
Google News